Single cell analysis of clonal architecture in acute myeloid leukaemia.
Alleles
Animals
Biomarkers, Tumor
Clonal Evolution
/ genetics
Disease Models, Animal
Genotype
Heterografts
High-Throughput Nucleotide Sequencing
Humans
Immunophenotyping
Leukemia, Myeloid, Acute
/ genetics
Mice
Mutation
Neoplastic Stem Cells
/ metabolism
Nucleophosmin
Recurrence
Single-Cell Analysis
/ methods
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
19
06
2018
accepted:
06
11
2018
revised:
31
10
2018
pubmed:
21
12
2018
medline:
14
8
2019
entrez:
21
12
2018
Statut:
ppublish
Résumé
We used single cell Q-PCR on a micro-fluidic platform (Fluidigm) to analyse clonal, genetic architecture and phylogeny in acute myeloid leukaemia (AML) using selected mutations. Ten cases of NPM1c mutant AML were screened for 111 mutations that are recurrent in AML and cancer. Clonal architectures were relatively simple with one to six sub-clones and were branching in some, but not all, patients. NPM1 mutations were secondary or sub-clonal to other driver mutations (DNM3TA, TET2, WT1 and IDH2) in all cases. In three of the ten cases, single cell analysis of enriched CD34
Identifiants
pubmed: 30568172
doi: 10.1038/s41375-018-0319-2
pii: 10.1038/s41375-018-0319-2
pmc: PMC6451634
mid: EMS80419
doi:
Substances chimiques
Biomarkers, Tumor
0
NPM1 protein, human
0
Npm1 protein, mouse
0
Nucleophosmin
117896-08-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1113-1123Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306–13.
doi: 10.1038/nature10762
Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–28.
doi: 10.1126/science.959840
Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356–61.
doi: 10.1038/nature09650
McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27:15–26.
doi: 10.1016/j.ccell.2014.12.001
Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13:795–806.
doi: 10.1038/nrg3317
Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.
doi: 10.1056/NEJMoa1301689
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.
doi: 10.1056/NEJMoa1516192
Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra118.
doi: 10.1126/scitranslmed.3004315
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33.
doi: 10.1038/nature13038
Miller CA, Wilson RK, Ley TJ. Genomic landscapes and clonality of de novo AML. N Engl J Med. 2013;369:1472–3.
doi: 10.1056/NEJMc1308782
de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346:251–6.
doi: 10.1126/science.1253462
Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47:458–68.
doi: 10.1038/ng.3273
Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155–60.
doi: 10.1038/nature13600
Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C, Radich JP. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med. 2015;7:281re282.
doi: 10.1126/scitranslmed.aaa0763
Klco JM, Spencer DH, Miller CA, Griffith M, Lamprecht TL, O’Laughlin M, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25:379–92.
doi: 10.1016/j.ccr.2014.01.031
Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, et al. Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016;213:1513–35.
doi: 10.1084/jem.20151775
Potter NE, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G, Titley I, et al. Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res. 2013;23:2115–25.
doi: 10.1101/gr.159913.113
Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010;115:1976–84.
doi: 10.1182/blood-2009-02-206565
Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–89.
doi: 10.1056/NEJMoa1112304
Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, et al. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica. 2015;100:e196–199.
doi: 10.3324/haematol.2014.115576
Rose D, Haferlach T, Schnittger S, Perglerova K, Kern W, Haferlach C. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31:11–17.
doi: 10.1038/leu.2016.163
Zhang X, Su J, Jeong M, Ko M, Huang Y, Park HJ, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48:1014–23.
doi: 10.1038/ng.3610
Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.
doi: 10.1038/nature10738
Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman-Grant A, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547:104–8.
doi: 10.1038/nature22993
Griffith M, Miller CA, Griffith OL, Krysiak K, Skidmore ZL, Ramu A, et al. Optimizing cancer genome sequencing and analysis. Cell Syst. 2015;1:210–23.
doi: 10.1016/j.cels.2015.08.015
Pellegrino M, Sciambi A, Treusch S, Durruthy-Durruthy R, Gokhale K, Jacob J, et al. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Res. 2018;28:1345–52.
doi: 10.1101/gr.232272.117
Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264–78.
doi: 10.1016/j.cell.2012.06.023
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372:601–12.
doi: 10.1056/NEJMoa1412098
Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, et al. CD34 + cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010;116:3907–22.
doi: 10.1182/blood-2009-08-238899
Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci, USA. 2014;111:2548–53.
doi: 10.1073/pnas.1324297111
Parkin B, Londono-Joshi A, Kang Q, Tewari M, Rhim AD, Malek SN. Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. J Clin Invest. 2017;127:3484–95.
doi: 10.1172/JCI91964
Kim T, Yoshida K, Kim YK, Tyndel MS, Park HJ, Choi SH, et al. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. Leukemia. 2016;30:295–302.
doi: 10.1038/leu.2015.264
Kronke J, Bullinger L, Teleanu V, Tschurtz F, Gaidzik VI, Kuhn MW, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122:100–8.
doi: 10.1182/blood-2013-01-479188
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.
doi: 10.1056/NEJMoa1408617
Sportoletti P, Varasano E, Rossi R, Mupo A, Tiacci E, Vassiliou G, et al. Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications. Leukemia. 2015;29:269–78.
doi: 10.1038/leu.2014.257
Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, Uren A, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011;43:470–5.
doi: 10.1038/ng.796
Mallardo M, Caronno A, Pruneri G, Raviele PR, Viale A, Pelicci PG, et al. NPMc + and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. Leukemia. 2013;27:2248–51.
doi: 10.1038/leu.2013.114
Mupo A, Celani L, Dovey O, Cooper JL, Grove C, Rad R, et al. A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia. 2013;27:1917–20.
doi: 10.1038/leu.2013.77
Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013;122:83–92.
doi: 10.1182/blood-2012-10-461749
Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33.
doi: 10.1056/NEJMoa1507471
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189–99.
doi: 10.1056/NEJMoa1716863
Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C. Cancer: evolution within a lifetime. Annu Rev Genet. 2014;48:215–36.
doi: 10.1146/annurev-genet-120213-092314
Greaves M. Evolutionary determinants of cancer. Cancer Discov. 2015;5:806–20.
doi: 10.1158/2159-8290.CD-15-0439
Piccirillo SGM, Colman S, Potter NE, van Delft FW, Lillis S, Carnicer M-J, et al. Genetic and functional diversity of propagating cells in glioblastoma. Stem Cell Rep. 2015;4:7–15.
doi: 10.1016/j.stemcr.2014.11.003
Greaves M. Cancer stem cells as ‘units of selection’. Evol Appl. 2013;6:102–8.
doi: 10.1111/eva.12017
Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–91.
doi: 10.1016/j.stem.2014.02.006
Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, et al. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. 2017;31:151–8.
doi: 10.1038/leu.2016.166